CT-322

01/01/2011 - "CT-322 treated tumors exhibited a significant reduction in tumor growth of 69%, a 2.8 times lower tumor surface area and fewer necrotic areas. "
11/27/2008 - "The efficacy of CT-322 was evaluated in vivo using two orthotopic pancreatic tumor models. "
12/01/2012 - "This study investigates the effects of the PEGylated Adnectins™ CT-322, a VEGFR2-inhibitor and AT580Peg40, an IGF-1R inhibitor, as monotherapy and in combination in a murine A673 xenograft tumor model. "
01/01/2011 - "This study investigates the antiangiogenic effects of the PEGylated Adnectin™, CT-322, in a murine Colo-205 xenograft tumor model. "
12/01/2012 - "Monotherapy with IGF-1R or CT-322 revealed equally a significant inhibition of tumor and vessel growth. "

08/01/2015 - "However, the phase II study done with CT-322 in recurrent glioblastoma does not reveal as promising results. "
02/01/2015 - "This study evaluated CT-322 in an open-label run-in/phase 2 setting to assess its efficacy and safety in recurrent glioblastoma. "
10/01/2009 - "CT-322, the first engineered FN3 to enter clinical development, is now entering Phase II trials for glioblastoma multiforme."
02/01/2015 - "Despite biological activity and a tolerable side effect profile, CT-322 failed to meet the prespecified threshold for efficacy in recurrent glioblastoma."
10/01/2012 - "Using an intracranial murine xenograft model (U87-EGFRvIII-luciferase), we demonstrate that CT322 inhibited glioblastoma growth in vivo and prolonged survival. "

11/27/2008 - "We conclude that CT-322 is an effective anti-VEGFR2 agent and that further investigation of CT-322 for the treatment of pancreatic cancer is warranted."
11/27/2008 - "Treatment with CT-322 was effective at preventing pancreatic tumor growth and metastasis in orthotopic xenograft and syngeneic models of pancreatic cancer. "
11/27/2008 - "The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer."

11/27/2008 - "Treatment with CT-322 was effective at preventing pancreatic tumor growth and metastasis in orthotopic xenograft and syngeneic models of pancreatic cancer. "

10/01/2012 - "CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy."